Neurogene Receives FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome
The FDA granted Breakthrough Therapy Designation to NGN-401, Neurogene's investigational AAV9 gene therapy being developed as a potential one-time treatment for Rett syndrome.
NGN-401 is advancing through the Embolden™ registrational trial.
